Lista de obras - Klaus Elenius - Dominio Público Uruguay

A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis

artículo científico publicado en 2000

A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester

artículo científico publicado en 1997

Activating ERBB4 mutations in non-small cell lung cancer

artículo científico publicado en 2015

Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation

artículo científico publicado en 1997

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

artículo científico publicado en 2005

Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival

artículo científico publicado en 2006

An unbiased in vitro screen for activating epidermal growth factor receptor mutations

scientific article published on 05 April 2019

Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor

artículo científico publicado en 2003

Association of Wwox with ErbB4 in breast cancer.

artículo científico publicado en 2007

CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.

artículo científico publicado en 2013

Cell death or survival promoted by alternative isoforms of ErbB4

scientific journal article

Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase

artículo científico publicado en 1999

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

artículo científico publicado en 2005

Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.

artículo científico publicado en 2009

DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation

artículo científico publicado en 2005

Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains

artículo científico publicado en 2007

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma

artículo científico publicado en 2010

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

artículo científico publicado en 2002

ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19

artículo científico publicado en 2013

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer

artículo científico publicado en 2014

Endothelial cell-matrix interactions.

artículo científico publicado en 2003

Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization ⬇️

artículo científico publicado el 15 de noviembre de 1992

ErbB targeted drugs and angiogenesis

artículo científico publicado en 2010

ErbB4 and its isoforms: patentable drug targets?

scientific article published on January 2008

ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family.

artículo científico publicado en 2004

ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo

artículo científico publicado en 2009

ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis

artículo científico publicado en 2014

Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants.

artículo científico publicado en 2000

Function of ERBB4 is determined by alternative splicing

artículo científico publicado en 2011

Function of the syndecans--a family of cell surface proteoglycans

artículo científico publicado en 1994

Genome-wide screen of gamma-secretase-mediated intramembrane cleavage of receptor tyrosine kinases.

artículo científico publicado en 2017

Growth factors induce 3T3 cells to express bFGF-binding syndecan

artículo científico publicado en 1992

Heparin-binding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen

scientific article published on 01 March 1998

High frequency of BRAF V600E mutations in ameloblastoma

artículo científico publicado en 2014

Human Metaplastic Breast Carcinoma and Decorin

artículo científico publicado en 2017

Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland

artículo científico publicado en 2014

Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases

scientific article published on 15 December 2020

Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.

artículo científico publicado en 2003

Induced expression of syndecan in healing wounds

artículo científico publicado en 1991

Interaction between marrow-derived human mesenchymal stem cells and peripheral blood mononuclear cells in endothelial cell differentiation.

artículo científico publicado en 2011

Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.

artículo científico publicado en 2012

Intra- and extracellular signaling by endothelial neuregulin-1

scientific article published on 18 April 2007

Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms.

artículo científico publicado en 2008

Mutated ERBB4: a novel drug target in metastatic melanoma?

artículo científico publicado en 2009

Neurite growth-promoting protein (amphoterin, p30) binds syndecan

scientific article published on 01 June 1992

Novel targets for the treatment of ameloblastoma

artículo científico publicado en 2014

O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.

artículo científico publicado en 2007

Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis

artículo científico publicado en 2014

Overview of wound healing

artículo científico publicado en 2001

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

artículo científico publicado en 2009

Potential of ErbB4 antibodies for cancer therapy.

artículo científico publicado en 2010

Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein

artículo científico publicado en 2012

Proteolytic Processing of ErbB4 in Breast Cancer

artículo científico publicado en 2012

Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth

artículo científico publicado en 2005

Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient.

artículo científico publicado en 2007

Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target

scientific article published on 20 October 2018

Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor.

artículo científico publicado en 2009

Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth

artículo científico publicado en 2010

Role of ErbB4 in breast cancer

scientific article published on 03 May 2008

SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase

artículo científico publicado en 2017

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

artículo científico publicado en 2006

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

artículo científico publicado en 2008

Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms

artículo científico publicado en 2009

Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-alpha.

artículo científico publicado en 1996

Syndecan from embryonic tooth mesenchyme binds tenascin

artículo científico publicado en 1991

Syndecan, a regulator of cell behaviour, is lost in malignant transformation ⬇️

artículo científico publicado el 1 de noviembre de 1991

Syndecan--a cell surface proteoglycan that selectively binds extracellular effector molecules

artículo científico publicado el 1 de enero de 1992

Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma

artículo científico publicado en 2012

The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.

artículo científico publicado en 2009

The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4

scientific journal article

The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration

scientific article published on 19 June 2020

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells

artículo científico publicado en 2006

Translation of a research-based genetic test on a rare syndrome into clinical service testing, with sotos syndrome as an example.

artículo científico publicado en 2012

Lista de obras de Klaus Elenius

A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis

A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester

Activating ERBB4 mutations in non-small cell lung cancer

Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival

An unbiased in vitro screen for activating epidermal growth factor receptor mutations

Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor

Association of Wwox with ErbB4 in breast cancer.

CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.

Cell death or survival promoted by alternative isoforms of ErbB4

Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.

DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation

Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer

Endothelial cell-matrix interactions.

Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization ⬇️

ErbB targeted drugs and angiogenesis

ErbB4 and its isoforms: patentable drug targets?

ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family.

ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo

ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis

Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants.

Function of ERBB4 is determined by alternative splicing

Function of the syndecans--a family of cell surface proteoglycans

Genome-wide screen of gamma-secretase-mediated intramembrane cleavage of receptor tyrosine kinases.

Growth factors induce 3T3 cells to express bFGF-binding syndecan

Heparin-binding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen

High frequency of BRAF V600E mutations in ameloblastoma

Human Metaplastic Breast Carcinoma and Decorin

Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland

Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases

Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.

Induced expression of syndecan in healing wounds

Interaction between marrow-derived human mesenchymal stem cells and peripheral blood mononuclear cells in endothelial cell differentiation.

Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.

Intra- and extracellular signaling by endothelial neuregulin-1

Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms.

Mutated ERBB4: a novel drug target in metastatic melanoma?

Neurite growth-promoting protein (amphoterin, p30) binds syndecan

Novel targets for the treatment of ameloblastoma

O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.

Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis

Overview of wound healing

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

Potential of ErbB4 antibodies for cancer therapy.

Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein

Proteolytic Processing of ErbB4 in Breast Cancer

Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth

Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient.

Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target

Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor.

Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth

Role of ErbB4 in breast cancer

SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms

Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-alpha.

Syndecan from embryonic tooth mesenchyme binds tenascin

Syndecan, a regulator of cell behaviour, is lost in malignant transformation ⬇️

Syndecan--a cell surface proteoglycan that selectively binds extracellular effector molecules

Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma

The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.

The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4

The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells

Translation of a research-based genetic test on a rare syndrome into clinical service testing, with sotos syndrome as an example.